Paper Details

  1. Home
  2. Paper Details

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

Author: BackstromJay, BeachC L, FenauxPierre, GoreSteven D, Hellström-LindbergEva, ListAlan F, McKenzieDavid, MuftiGhulam J, SantiniValeria, SeymourJohn F, SilvermanLewis R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effectiveness of azacitidine (AZA) to conventional care regimens (CCR) in patients with higher-risk myelodysplastic syndromes (MDS). AZA significantly improved overall survival and was well tolerated compared to CCR.
Paper Details　
Original Abstract of the Article :
This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated overall survival (OS) and tolerability in the subset of 87 elderly (≥ 75 years) patients with higher-risk MDS (FAB: RAEB, RAEB-t, CMML and IPSS: Int-2 or High) from the AZA-001 trial. Patients were rand...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/20451404

データ提供：米国国立医学図書館（NLM）

Azacitidine: A Beacon of Hope for Elderly Patients with Higher-Risk Myelodysplastic Syndromes

The treatment of [higher-risk myelodysplastic syndromes (MDS)] is a challenging task, particularly in [elderly patients]. This study compares the efficacy and tolerability of [azacitidine (AZA)] to [conventional care regimens (CCR)] in elderly patients with higher-risk MDS. Imagine the desert of MDS as a treacherous landscape, where elderly patients face a difficult journey to recovery.

A Beacon of Hope: Azacitidine Offers Improved Survival for Elderly Patients with Higher-Risk MDS

The researchers found that AZA significantly improved [overall survival (OS)] compared to CCR, with a [2-year OS rate of 55%] for AZA-treated patients, compared to [15%] for CCR-treated patients. This is like finding a life-giving oasis in the desert, providing a refuge and a chance for survival. This study suggests that AZA can be a valuable treatment option for elderly patients with higher-risk MDS.

A Gentle Approach: Azacitidine Offers Improved Tolerability for Elderly Patients

The study also found that AZA was generally well-tolerated, with a lower incidence of [grade 3-4 hematological side effects] compared to CCR. This is like finding a gentle camel, capable of carrying the traveler safely through the challenging desert landscape. This finding suggests that AZA offers a more tolerable treatment option for elderly patients, minimizing the burden of side effects.

Dr. Camel's Conclusion

This study, like a caravan guided by a wise leader, offers hope for elderly patients with higher-risk MDS. The findings reveal the remarkable effectiveness and tolerability of azacitidine, providing a beacon of hope for patients navigating this challenging journey. This research underscores the importance of personalized treatment approaches, ensuring that patients receive the best possible care to improve their quality of life and extend their survival.

Date :
  1. Date Completed 2011-03-10
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20451404

DOI: Digital Object Identifier

NIHMS490287

Related Literature

Article Analysis
・Effects of azacitidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.